GLP1R and type 2 diabetes mellitus: Both of these classes of agents are associated with a low propensity to induce hypoglycemia; are either weight neutral (DPP-4is) or are associated with weight loss (GLP1-RA), and have demonstrated either neutrality or benefit in cardiovascular outcome trials (CVOTs) in type 2 diabetes [2].